After Biosimilar Fee Collections Fall Short, US FDA Modifies Carryover Spend-Down Plan
Executive Summary
A lower-than-expected number of fee-paying application submissions in FY 2018 resulted in the agency spending approximately $9.7m more than anticipated from its user fee carryover balance, leading to a reset of spend-down targets for the remainder of BsUFA II.
You may also be interested in...
BsUFA Revenue Missed Estimates Again In FY2019
US FDA said that total BsUFA obligations also decreased compared to estimates, but maintains optimism about future revenue increases.
Biosimilar User Fee Revenue Missed Estimates Again In FY 2019, Spending Reduced
US FDA said that total BsUFA obligations also decreased compared to estimates, but maintains optimism about future revenue increases.
Playing It Safe? Hahn's Biosimilar View
US FDA Commissioner nominee gave a general, scripted answer to a question about biologic patents, but did Stephen Hahn inadvertently go against the agency's stance on the issue?